Cyclophosphamide for scleroderma interstitial lung disease
- 16 February 2007
- journal article
- editorial
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 16 (3) , 393-395
Abstract
Systemic sclerosis (scleroderma) is a chronic debilitating disease that is caused by the occurrence of fibrotic changes and vascular abnormalities at various levels such as: skin, lungs, kidneys or heart. Lung involvement in scleroderma is represented by scleroderma interstitial lung disease and by pulmonary arterial hypertension, and is one of the leading causes of mortality in this disease. Pulmonary arterial hypertension can be successfully treated with specific therapies such as sildenafil, bosentan or epoprostenol, whereas only cyclophosphamide has been shown to be effective for interstitial lung disease. The discussed study has shown that cyclophosphamide improved lung function, functional status and health-related quality of life, and reduced dyspnea in scleroderma patients. Most of these patients had acute alveolitis although higher incidences of treatment-related leukopenia and neutropenia were also detected.Keywords
This publication has 7 references indexed in Scilit:
- Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung diseaseRheumatology International, 2006
- Cyclophosphamide versus Placebo in Scleroderma Lung DiseaseNew England Journal of Medicine, 2006
- Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centreClinical Rheumatology, 2006
- Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung diseaseRheumatology, 2006
- Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigationsAnnals of the Rheumatic Diseases, 2005
- Cyclophosphamide Is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and AlveolitisAnnals of Internal Medicine, 2000
- Evaluation and management of scleroderma lung disease using bronchoalveolar lavageThe American Journal of Medicine, 1990